《2015年世界卫生组织慢性乙型肝炎病毒感染预防、关怀和治疗指南》解读:无创肝纤维化评估、抗病毒治疗策略和国家防治计划实施

胡晓云; 刘智泓; 孙剑

doi:10.3969/j.issn.1001-5256.2015.06.003

《2015年世界卫生组织慢性乙型肝炎病毒感染预防、关怀和治疗指南》解读:无创肝纤维化评估、抗病毒治疗策略和国家防治计划实施

DOI: 10.3969/j.issn.1001-5256.2015.06.003

南方医科大学南方医院感染科暨肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 172
- HTML全文浏览量: 9
- PDF下载量: 1262
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Explanation of the “Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection 2015”: non-invasive assessment of liver fibrosis,treatment strategy and implementation of national programs

Department of Infectious Disease and Hepatology Unit,Nanfang Hospital,Southern Medical University

摘要

摘要:
<正>世界卫生组织(WHO)继2014年发布丙型肝炎防治指南之后,2015年3月在土耳其伊斯坦布尔召开的亚太肝脏病年会上发布了首个慢性乙型肝炎(CHB)的预防、关怀和治疗指南(以下简称WHO乙型肝炎防治指南)。与已有的欧洲肝病学会(EASL)、亚太肝病学会(APASL)、美国肝病学会(AASLD)乙型肝炎防治指南不同的是,WHO乙型肝炎防治指
- 肝炎,乙型,慢性 /
- 肝硬化 /
- 发展中国家 /
- 世界卫生组织 /
- 指南
- hepatitis B,chronic /
- liver cirrhosis /
- developing countries /
- World Health Organization /
- guidelines

HTML全文

参考文献(18)

[1]LOK AS,MCMAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.

[2]European Association For The Study Of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[3]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(3):531-561.

[4]CHEN YP,LIANG XE,DAI L,et al.Improving transient elastography performance for detecting hepatitis B cirrhosis[J].Dig Liver Dis,2012,44(1):61-66.

[5]CHEN YP,LIANG XE,ZHANG Q,et al.Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B[J].J Gastroenterol Hepatol,2012,27(7):1219-1226.

[6]WHO Guidelines Approved by the Guidelines Review Committee.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:recommendations for a public health approach[M].Geneva:World Health Organization,2013.

[7]LIANG J,TANG YF,WU FS,et al.Entecavir versus lamivudine for the treatment of chronic hepatitis B:a systematic review[J].Pharmazie,2012,67(11):883-890.

[8]ZHAO P,LIU W,ZHAO J,et al.Comparison of the 48-week efficacy between entecavir and adefovir in HBe Ag-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B:a meta-analysis[J].Virol J,2011,8:75.

[9]MARCELLIN P,HEATHCOTE EJ,BUTI M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.

[10]PRICE H,DUNN D,PILLAY D,et al.Suppression of HBV by tenofovir in HBV/HIV coinfected patients:a systematic review and meta-analysis[J].PLo S One,2013,8(7):e68152.

[11]MURRAY KF,SZENBORN L,WYSOCKI J,et al.Randomized,placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B[J].Hepatology,2012,56(6):2018-2026.

[12]FUNG SK,CHAE HB,FONTANA RJ,et al.Virologic response and resistance to adefovir in patients with chronic hepatitis B[J].J Hepatol,2006,44(2):283-290.

[13]SARRI G,WESTBY M,BERMINGHAM S,et al.Diagnosis and management of chronic hepatitis B in children,young people,and adults:summary of NICE guidance[J].BMJ,2013,346:f3893.

[14]LOK AS,ZOULIM F,LOCARNINI S,et al.Antiviral drug-resistant HBV:standardization of nomenclature and assays and recommendations for management[J].Hepatology,2007,46(1):254-265.

[15]PALLIER C,CASTRA L,SOULIER A,et al.Dynamics of hepatitis B virus resistance to lamivudine[J].J Virol,2006,80(2):643-653.

[16]HUANG ZB,ZHAO SS,HUANG Y,et al.Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B:a systematic review and meta-analysis[J].Clin Ther,2013,35(12):1997-2006.

[17]LIM LG,AUNG MO,SEET BL,et al.Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance[J].World J Gastroenterol,2010,16(37):4691-4696.

[18]LIANG Y,JIANG J,SU M,et al.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy[J].Aliment Pharmacol Ther,2011,34(3):344-352.

施引文献

资源附件(0)

访问统计